- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Lower Tumor Burden Associated With Improved ORR With Liso-Cel in R/R CLL/SLL
June 17th 2024, 4:09pm
European Hematology Association Congress
Lower disease burden improves response to liso-cel treatment in CLL/SLL, reports TRANSCEND CLL 004 trial.
Dr Samarasinghe on the Feasibility of First-Line Blinatumomab in Down Syndrome B-ALL
June 16th 2024, 2:57pm
European Hematology Association Congress
Sujith Samarasinghe, MD, discusses key results from the phase 2 ALLTOGETHER 1 DS trial in Down Syndrome B-cell acute lymphoblastic leukemia.
Dr Trudel on Results From the DREAMM-7 Trial of BVd in R/R Multiple Myeloma
June 16th 2024, 2:53pm
European Hematology Association Congress
Suzanne Trudel, MSc, MD, discusses key results and subgroup analyses from the phase 3 DREAMM-7 trial of BVd in relapsed/refractory multiple myeloma.
Zanubrutinib Associated With Cost Savings and QALY Benefits vs Acalabrutinib in B-Cell Malignancies
June 15th 2024, 6:05pm
European Hematology Association Congress
Zanubrutinib was associated with improved cost savings and quality-adjusted life year benefits vs acalabrutinib in B-cell malignancies.
ATRA/ATO Regimen Improves EFS in Newly Diagnosed, High-risk APL
June 15th 2024, 5:56pm
European Hematology Association Congress
Arsenic trioxide plus all-trans retinoic acid & idarubicin improved EFS vs standard ATRA and anthracycline-based chemotherapy in high-risk APL.
Glofitamab Plus Gemcitabine/Oxaliplatin Shows Survival Benefit in Transplant-Ineligible R/R DLBCL
June 15th 2024, 5:46pm
European Hematology Association Congress
Adding fixed-duration glofitamab-gxbm (Columvi) to gemcitabine and oxaliplatin led to a statistically significant and clinically meaningful improvement in survival vs rituximab (Rituxan) plus gemcitabine/oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.
Dr Bertossi on the Prognostic Role of TP53 Mutations in CLL
June 15th 2024, 1:50pm
European Hematology Association Congress
Consuelo Bertossi, MD, discusses the role of TP53 mutations and their prognostic significance in chronic lymphocytic leukemia.
Dr Grunwald on the Rates of Disease Progression in Low-Risk Myelofibrosis
June 15th 2024, 1:46pm
European Hematology Association Congress
Michael R. Grunwald, MD, FACP, discusses disease progression in patients with low-risk myelofibrosis enrolled in the prospective MOST study.
Zanubrutinib Plus Obinutuzumab/Venetoclax Is Safe, Elicits Responses in Older Patients With Untreated MCL
June 15th 2024, 1:11pm
European Hematology Association Congress
The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.
Earlier Use of Acalabrutinib Associated With Improved Survival in CLL
June 14th 2024, 8:14pm
European Hematology Association Congress
Earlier use of acalabrutinib was associated with improved survival in patients with chronic lymphocytic leukemia.
CAR T-Cell Therapy Is Safe, Feasible in Outpatient Setting for NHL
June 14th 2024, 7:59pm
European Hematology Association Congress
The administration of CAR T-cell therapy in the outpatient setting was deemed feasible and safe in patients with relapsed/refractory NHL.
Ponatinib Regimen Shows Long-term Efficacy in Acute Lymphoblastic Leukemia
June 14th 2024, 7:53pm
European Hematology Association Congress
Ponatinib, chemo, and alloHSCT offer long-term survival in adult Ph+ ALL, per 4-year PONALFIL trial data at 2024 EHA Congress.
Englumafusp alfa/Glofitamab Combo Shows Early Responses in R/R Aggressive non-Hodgkin Lymphoma
June 14th 2024, 7:18pm
European Hematology Association Congress
Englumafusp alfa plus glofitamab showed activity and tolerability in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Anemia Does Not Diminish Benefit With Ruxolitinib Treatment in Myelofibrosis
June 14th 2024, 6:52pm
European Hematology Association Congress
Patients with new or worsening anemia from their myelofibrosis did not experience lessened clinical benefit of ruxolitinib treatment.
CD7-Directed CAR T-Cell Therapy WU-CART-007 Is Safe in R/R T-ALL/LBL
June 14th 2024, 6:36pm
European Hematology Association Congress
The CD7-targeted CAR T-cell therapy WU-CART-007 had a manageable safety profile and elicited preliminary efficacy signals in relapsed/refractory T-ALL/LBL.
Frontline Blinatumomab Demonstrates “Impressive” Activity in Down Syndrome B-ALL
June 14th 2024, 6:12pm
European Hematology Association Congress
Blinatumomab consolidation improved MRD clearance over chemotherapy in DS B-ALL patients, according to ALLTogether1 DS study results.
Disease Duration, Elevated WBC Count, and VAF Predict Disease Progression in Polycythemia Vera
June 14th 2024, 6:11pm
European Hematology Association Congress
Time from diagnosis, elevated WBC count, and VAF were all significantly associated with an increased risk of disease progression of polycythemia vera.
Dr Kamdar on Results From a Subgroup Analysis of Liso-Cel in MCL
June 14th 2024, 6:03pm
European Hematology Association Congress
Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.
Dr Aldoss on Responses With WU-CART-007 After Enhanced Lymphodepletion in R/R T-ALL/LBL
June 14th 2024, 5:59pm
European Hematology Association Congress
Ibrahim Aldoss, MD, discusses the impact of enhanced lymphodepletion on responses with WU-CART-007 in relapsed/refractory T-ALL/LBL.
HOVON-146 Study Shows Blinatumomab Boosts B-ALL Outcomes
June 14th 2024, 5:47pm
European Hematology Association Congress
HOVON-146 showed integrating blinatumomab into pre-phase and consolidation therapy improved outcomes in newly diagnosed B-ALL.